Hosted on MSN
Atomic-level mapping of amorphous diabetes drug reveals hydrogen bonds as key to stability
Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated on a GLP-1 receptor agonist candidate for diabetes and obesity treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback